Viral Clearance Market - Regional Analysis
North America Market Insights
The North America viral clearance market is projected to account for a leading share of 36% by the end of 2037. The growth can be attributed to the significant investment of resources into biologics manufacturing, including viral filtration systems in public health systems. The Public Health Agency of Canada (PHAC) has also started committing funding focused on the containment of infectious diseases, biosafety. The British Columbia and Alberta health ministries are exploring governments directing funding to viral filtration systems in public and private hospitals. Industry players like Innovative Medicines Canada and BioteCanada are advancing the development of bioprocessing capacity domestically to reduce reliance on imported biologics. There is a key shift in the use of high-throughput and viral filtration technologies for producing gene- and cell-based therapies.
More investments are made in U.S. Viral Clearance. This growth will continue and can already be seen in investments geared towards infection control and advanced therapeutic biologics. The CDC and AHRQ reports investments into Viral Clearance made up 8% of the total federal healthcare budget in 2023. Since the National Institute of Health and HHS have funded several years of research in viral risk mitigation, this aspect of investment has also helped spur biotech innovations. Organizations such as the American Medical Association (AMA) and Biotechnology Innovation Organization (BIO) have stimulated clinical research partnerships and funded decentralized modes of treatment delivery. Ongoing initiatives by PhRMA have likewise strengthened market confidence to develop new drug innovations and support new early access programs for public use.
In addition, the market continues to evolve through new contract prescription agreements and pledges via Operation Warp Speed and public-private collaborations for improved pandemic preparedness and initiatives. The trend is leaning towards Viral Clearance being a part of the biopharmaceutical manufacturing and cell therapy workflow processes. National surveillance systems published by the CDC will enhance early detection of pathogens and increase the critical need for upstream clearance technologies in both the bioprocessing process and the transfusion process. Overall, support of government involvement and technological integration will continue to be the levers of growth for the U.S. market for viral clearance.
Asia Pacific Market Insights
The Asia Pacific viral clearance market is poised to hold a revenue share of 23% throughout the forecast period. The key drivers of growth in the region are the biopharmaceutical production, infectious disease control, and disease biosafety initiatives in countries such as China, Japan, India, South Korea, and Malaysia. Japan has the next largest market share with 11% of the healthcare budget contingent on allocation to viral clearance. In 2024, the government of Japan earmarked 11% of the new 2024 healthcare budget for viral clearance. Moreover, with considerable investment and treatment of increasing individuals, the region leads these innovations and technology risk solid removals capabilities over the next decade.
By 2037, India is anticipated to have the largest compound annual growth rate (CAGR) of any country in the Asia Pacific virus clearance market party due to government investment in healthcare and local biologics manufacturing. The biopharma sector in India has benefited from USDA support in the case of the Department of Biotechnology and ICMR organizations, which have all made investments that create decisions in favor of the viral filtration infrastructure directly supporting vaccines, antibody preparations, and plasma therapies. The government investment and policies associated with the National Health Mission, and the promotion of local biologics production through the Make in India Initiative, have been successful in fostering domestic production of good manufacturing practices (GMP) compliant virus clearance readiness assets.
Over the past few years, global companies have partnered with local producers by leveraging funding support from agency sources such as the Biotechnology Industry Research Assistance Council (BIRAC) to successfully advance the transfer of technology in India by engaging with the local biopharma community for innovation in clinical and application settings related to viral clearance processes. The surge of biopharma demand in India has prepared India to optimize the growth opportunity to drive and ultimately meet the anticipated hyper-growth in demand and supply associated with virus clearance solutions.
